Loading stock data…
TARA
$3.97-0.07 (-1.73%)
After Hours$3.97+0.00 (+0.00%)· Last close Jun 9
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Protara Therapeutics, Inc. in the Healthcare sector is trading at $3.97 with a market capitalization of $237M. Wall Street consensus targets $26.57 (7 analysts), implying a +569.3% move over the next 12 months. The stock is currently 49% below its 52-week high of $7.82, remaining 24.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +569.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.97
Potential Downside
0%
Whystock Fair Value$3.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$26.57+569.3%
Range$24.00 – $30.00
Fundamentals
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$237.18M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.94%
Volume
Today's trading volume
982,578
Recent News
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.
One Protara Therapeutics Insider Raised Their Stake In The Previous Year
From what we can see, insiders were net buyers in Protara Therapeutics, Inc.'s ( NASDAQ:TARA ) during the past 12...
Protara Therapeutics: Q4 Earnings Snapshot
NEW YORK (AP) — Protara Therapeutics, Inc. TARA) on Tuesday reported a loss of $17.3 million in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 37 cents.
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf
Protara Therapeutics (NASDAQ:TARA) executives outlined progress across the company’s two clinical-stage programs during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, highlighting updated interim results from its ongoing non-muscle invasive bladder cancer (NMIBC) s
Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU
Protara Therapeutics (NASDAQ:TARA) shared updated interim data from its ongoing Phase 2, open-label ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. Management said